part Section 1: Integration of Cell Cycle Control Pathways and the Oppertunities for Targeting -- chapter 1 Cell Cycle Dynamics and the Challenges for CDK Targeting -- chapter 2 Functional Regulation of CIP/KIP CDK Inhibitors -- chapter 3 Mouse Models to Study the In Vivo Fuction of Cyclin-Dependent Kinases in Normal Homeostasis and Tumor Development -- chapter 4 Cyclin-Dependent Kinase Inhibitors and Vascular Disease -- part Section II: CDK Inhibitors: Targets and Their Evaluation -- chapter 5 Evaluation of CDK Inhibitor Selectivity: From Affinity Chromatography to Yeast Genetics -- chapter 6 Development of CDK Inhibitors as Anticancer Agents: From Rational Design to CDK4-Specific Inhibition -- chapter 7 Three-Dimensional Structures of Cyclin- Dependent Kinases and Their Inhibitor Complexes -- part Section III: CDK Inhibitors: Chemistry Focus -- chapter 8 Cyclin-Dependent Kinase Small Molecule Modulators for Cancer Therapy -- chapter 9 (R)-Roscovitine (CYC202, Seliciclib) -- chapter 10 Development, Selectivity, and Application of Paullones, a Family of CDK Inhibitors -- chapter 11 Discovery of BMS-387032, a Potent Cyclin-Dependent Kinase Inhibitor in Clinical Development -- chapter 12 Oxindole Inhibitors of Cyclin-Dependent Kinases as Anti-Tumor Agents -- chapter 13 Indenopyrazoles as Cyclin-Dependent Kinase Inhibitors -- chapter 14 Development of Indolocarbazoles as Cyclin D1/CDK4 Inhibitors -- chapter 15 Pyrazoles as Efficient Adenine-Mimetic Heterocycles for the Discovery of CDK Inhibitors -- chapter 16 Pyrazolo[3,4-d]pyrimidin- 4-ones: Exploring the Structural Determinants of Potency and Selectivity in Cyclin-Dependent Kinase Inhibition -- part Section IV: Therapeutic Perspective -- chapter 17 Cyclin-Dependent Kinase Inhibitors and Combination Therapy: Experimental and Clinical Status -- chapter 18 CDK Inhibitors as Anticancer Agents: Perspectives for the Future.